Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. more
Time Frame | THTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 16.9% | -3.35% | -2.97% |
1-Month Return | 38.33% | -3.49% | -0.66% |
3-Month Return | 36.07% | -12.6% | 2.71% |
6-Month Return | 31.75% | -6.91% | 7.21% |
1-Year Return | 3.75% | 1.19% | 23.04% |
3-Year Return | -86.83% | -0.21% | 28.43% |
5-Year Return | -84.91% | 33.09% | 82.88% |
10-Year Return | 38.33% | 93.55% | 184.63% |
Nov '19 | Nov '20 | Nov '21 | Nov '22 | Nov '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 63.22M | 66.05M | 69.82M | 80.06M | 81.76M | [{"date":"2019-11-30","value":77.32,"profit":true},{"date":"2020-11-30","value":80.78,"profit":true},{"date":"2021-11-30","value":85.4,"profit":true},{"date":"2022-11-30","value":97.91,"profit":true},{"date":"2023-11-30","value":100,"profit":true}] |
Cost of Revenue | 26.08M | 26.90M | 23.26M | 26.28M | 19.64M | [{"date":"2019-11-30","value":96.93,"profit":true},{"date":"2020-11-30","value":100,"profit":true},{"date":"2021-11-30","value":86.46,"profit":true},{"date":"2022-11-30","value":97.68,"profit":true},{"date":"2023-11-30","value":72.99,"profit":true}] |
Gross Profit | 37.14M | 39.15M | 46.56M | 53.78M | 62.13M | [{"date":"2019-11-30","value":59.78,"profit":true},{"date":"2020-11-30","value":63.02,"profit":true},{"date":"2021-11-30","value":74.95,"profit":true},{"date":"2022-11-30","value":86.56,"profit":true},{"date":"2023-11-30","value":100,"profit":true}] |
Gross Margin | 58.75% | 59.27% | 66.69% | 67.17% | 75.99% | [{"date":"2019-11-30","value":77.32,"profit":true},{"date":"2020-11-30","value":78,"profit":true},{"date":"2021-11-30","value":87.76,"profit":true},{"date":"2022-11-30","value":88.4,"profit":true},{"date":"2023-11-30","value":100,"profit":true}] |
Operating Expenses | 45.65M | 57.11M | 71.80M | 93.69M | 72.76M | [{"date":"2019-11-30","value":48.73,"profit":true},{"date":"2020-11-30","value":60.96,"profit":true},{"date":"2021-11-30","value":76.64,"profit":true},{"date":"2022-11-30","value":100,"profit":true},{"date":"2023-11-30","value":77.66,"profit":true}] |
Operating Income | (8.51M) | (17.96M) | (25.24M) | (39.91M) | (10.63M) | [{"date":"2019-11-30","value":-851300000,"profit":false},{"date":"2020-11-30","value":-1795700000,"profit":false},{"date":"2021-11-30","value":-2523600000,"profit":false},{"date":"2022-11-30","value":-3990800000,"profit":false},{"date":"2023-11-30","value":-1062700000,"profit":false}] |
Total Non-Operating Income/Expense | (3.98M) | (9.80M) | (12.85M) | (13.10M) | (23.50M) | [{"date":"2019-11-30","value":-398300000,"profit":false},{"date":"2020-11-30","value":-979700000,"profit":false},{"date":"2021-11-30","value":-1285200000,"profit":false},{"date":"2022-11-30","value":-1310200000,"profit":false},{"date":"2023-11-30","value":-2349700000,"profit":false}] |
Pre-Tax Income | (12.50M) | (22.65M) | (31.66M) | (46.79M) | (23.54M) | [{"date":"2019-11-30","value":-1249600000,"profit":false},{"date":"2020-11-30","value":-2265100000,"profit":false},{"date":"2021-11-30","value":-3166200000,"profit":false},{"date":"2022-11-30","value":-4679400000,"profit":false},{"date":"2023-11-30","value":-2353600000,"profit":false}] |
Income Taxes | 4.99M | 16.00K | 63.00K | 443.00K | 421.00K | [{"date":"2019-11-30","value":100,"profit":true},{"date":"2020-11-30","value":0.32,"profit":true},{"date":"2021-11-30","value":1.26,"profit":true},{"date":"2022-11-30","value":8.88,"profit":true},{"date":"2023-11-30","value":8.44,"profit":true}] |
Income After Taxes | (17.49M) | (22.67M) | (31.73M) | (47.24M) | (23.96M) | [{"date":"2019-11-30","value":-1748600000,"profit":false},{"date":"2020-11-30","value":-2266700000,"profit":false},{"date":"2021-11-30","value":-3172500000,"profit":false},{"date":"2022-11-30","value":-4723700000,"profit":false},{"date":"2023-11-30","value":-2395700000,"profit":false}] |
Income From Continuous Operations | (12.50M) | (22.67M) | (31.73M) | (47.24M) | (23.96M) | [{"date":"2019-11-30","value":-1249600000,"profit":false},{"date":"2020-11-30","value":-2266700000,"profit":false},{"date":"2021-11-30","value":-3172500000,"profit":false},{"date":"2022-11-30","value":-4723700000,"profit":false},{"date":"2023-11-30","value":-2395700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-11-30","value":"-","profit":true},{"date":"2020-11-30","value":"-","profit":true},{"date":"2021-11-30","value":"-","profit":true},{"date":"2022-11-30","value":"-","profit":true},{"date":"2023-11-30","value":"-","profit":true}] |
Net Income | (12.50M) | (22.67M) | (31.73M) | (47.24M) | (23.96M) | [{"date":"2019-11-30","value":-1249600000,"profit":false},{"date":"2020-11-30","value":-2266700000,"profit":false},{"date":"2021-11-30","value":-3172500000,"profit":false},{"date":"2022-11-30","value":-4723700000,"profit":false},{"date":"2023-11-30","value":-2395700000,"profit":false}] |
EPS (Diluted) | (0.16) | (0.29) | (0.34) | (0.50) | (0.66) | [{"date":"2019-11-30","value":-16,"profit":false},{"date":"2020-11-30","value":-29,"profit":false},{"date":"2021-11-30","value":-34,"profit":false},{"date":"2022-11-30","value":-50,"profit":false},{"date":"2023-11-30","value":-66,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
THTX | |
---|---|
Cash Ratio | 0.73 |
Current Ratio | 1.08 |
Quick Ratio | 0.97 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
THTX | |
---|---|
ROA (LTM) | 11.76% |
ROE (LTM) | -1116.86% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
THTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.28 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
THTX | |
---|---|
Trailing PE | NM |
Forward PE | 19.92 |
P/S (TTM) | 0.98 |
P/B | 20.13 |
Price/FCF | 18 |
EV/R | 1.20 |
EV/Ebitda | 8.75 |
Theratechnologies Inc. (THTX) share price today is $1.66
Yes, Indians can buy shares of Theratechnologies Inc. (THTX) on Vested. To buy Theratechnologies Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in THTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Theratechnologies Inc. (THTX) via the Vested app. You can start investing in Theratechnologies Inc. (THTX) with a minimum investment of $1.
You can invest in shares of Theratechnologies Inc. (THTX) via Vested in three simple steps:
The 52-week high price of Theratechnologies Inc. (THTX) is $2.58. The 52-week low price of Theratechnologies Inc. (THTX) is $1.08.
The price-to-earnings (P/E) ratio of Theratechnologies Inc. (THTX) is
The price-to-book (P/B) ratio of Theratechnologies Inc. (THTX) is 20.13
The dividend yield of Theratechnologies Inc. (THTX) is 0.00%
The market capitalization of Theratechnologies Inc. (THTX) is $82.25M
The stock symbol (or ticker) of Theratechnologies Inc. is THTX